CVM

CEL-SCI Corporation (CEL-SCI) - 10-K Summary

Business Context and Reporting Period

Reporting Period: Fiscal year ended September 30, 2003.
Business Overview: CEL-SCI is a biotechnology company focused on the research and development of immunotherapies, primarily MULTIKINE (a cytokine cocktail for cancer treatment) and CEL-1000 (a peptide for infectious diseases and bio-terrorism defense). The company has no commercial product sales and relies on grant revenue, equity financing, and convertible debt to fund operations. As of December 1, 2003, the company had 65,121,384 shares of common stock outstanding.

Key Financial Metrics (Fiscal Year 2003)

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $2.0 million (24%) compared to 2002, driven primarily by a significant reduction in Research and Development (R&D) expenses.
• R&D Expense Decline: R&D expenses dropped from $4.7 million in 2002 to $1.9 million in 2003. Management attributes this to the completion of the current production run of MULTIKINE in fiscal 2002.
• Increased G&A Expenses: General and Administrative expenses rose by $532,000 (30%). This increase was partially offset by a $593,472 reversal of a compensation charge in 2002 related to repriced employee options.
• Revenue Decline: Grant revenue decreased by $66,735 due to the winding down of a specific project, though four new grants totaling approximately $170,750 were secured in 2003.
• Debt Conversion: Significant portions of Series G and Series H convertible notes were converted into common stock during the year, reducing principal debt obligations but increasing share count.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Resources: The company has no commercial revenue and relies on external financing. Management plans to fund operations through existing cash, an equity line of credit with Rubicon Group Ltd. (up to $10 million, though not yet effective as of filing), and further equity/debt issuances. Management believes funds will be sufficient for fiscal 2004 but notes that further expenditure reductions may delay product development.
• Product Development:
  • MULTIKINE: Clinical trials in head and neck cancer and cervical dysplasia (HPV/HIV co-infected women) have shown promising preliminary results (e.g., 71% elimination/reduction of dysplasia in one study). However, FDA approval is not guaranteed, and commercialization is years away.
  • CEL-1000: Preclinical studies show 100% protection against malaria in mouse models. The company has secured multiple government grants (NIH, Navy) for development against viral encephalitis, herpes, and bio-terrorism agents.
• Key Risks:
  • Regulatory Approval: No assurance that products will receive FDA or foreign regulatory approval.
  • Financing: No assurance that additional capital will be available on favorable terms.
  • Dilution: Significant potential dilution exists due to outstanding warrants, options, and convertible notes (over 10 million shares potentially issuable).
  • Competition: Intense competition from large pharmaceutical companies with greater resources.

Investor Verification Checklist

• Cash Runway: Verify current cash balance against the $1.85 million in contractual obligations due in 2004 (including notes payable to Cambrex and Covance).
• Equity Line Status: Confirm the effectiveness of the SEC registration statement required to activate the $10 million Rubicon Group equity line of credit.
• Debt Covenants: Review terms of the Cambrex note (due Jan 2, 2004) and Covance note, including the 10% and 2-4% royalty-like payments on future financings.
• Dilution Impact: Assess the impact of the ~10.6 million shares issuable via options and warrants on future earnings per share.
• Clinical Milestones: Monitor the June 1, 2004 deadline for Eastern Biotech to enroll 20 patients in a head and neck cancer trial to retain distribution rights.